Flavonoids and prenylhydroquinones from the prepared folium of Epimedium sagittatum Maxim. and their inhibition against phosphodiesterase5A.
Flavonoid
Male erectile dysfunction
Phosphodiesterase-5A inhibitory activity
Prenylhydroquinone
The prepared folium of Epimedium sagittatum maxim.
Journal
Fitoterapia
ISSN: 1873-6971
Titre abrégé: Fitoterapia
Pays: Netherlands
ID NLM: 16930290R
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
03
01
2023
revised:
24
02
2023
accepted:
25
02
2023
medline:
21
6
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
An effort to identify novel active substances of the prepared folium of Epimedium sagittatum Maxim. (PFES) that was an important herb for male erectile dysfunction (ED) was taken. At present, phosphodiesterase-5A (PDE5A) is the most important target of new drugs for the treatment of ED. Therefore, the inhibition ingredients in PFES were systematically screened for the first time in this study. Eleven compounds, including eight new flavonoids and three prenylhydroquinones were isolated: sagittatosides DN (1-11), and their structures were elucidated by spectra and chemical analyses. Among them, a novel prenylflavonoid with oxyethyl group (1) was obtained and three prenylhydroquinones (9-11) were firstly isolated from Epimedium. All compounds were analyzed for the inhibition against PDE5A by molecular docking, and they all showed significant binding affinity as same as sildenafil. Their inhibitory activities were verified, and the results showed compound 6 had significant inhibition against PDE5A1. The isolation of new flavonoids and prenylhydroquinones with inhibitory activities of PDE5A from PFES implied that this herb might be a good source for the treatment of ED agents finding.
Identifiants
pubmed: 36863569
pii: S0367-326X(23)00040-0
doi: 10.1016/j.fitote.2023.105465
pii:
doi:
Substances chimiques
Flavonoids
0
Sildenafil Citrate
BW9B0ZE037
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105465Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest and declarations of interest.